CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 35 enrolled
Drug / intervention
Clofarabine, Cyclophosphamidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01462253
NCT01462253Phase 2Completed
CompareCT.gov

"A Phase II Study With a Sequential Clofarabine-cyclophosphamide Combination Schedule as Salvage Therapy for Refractory and Relapsed Acute Lymphoblastic Leukemia (ALL) in Adult Patients"

Gruppo Italiano Malattie EMatologiche dell'Adulto·interventional·Posted Oct 31, 2011·Updated Jan 25, 2019

In Brief

A Phase 2 clinical trial evaluating Clofarabine, Cyclophosphamide for Acute Lymphoblastic Leukemia. Completed, enrolled 35 participants across 27 sites.

Detailed Summary

This is a multicentric, prospective pilot trial testing a Clofarabine-Cyclophosphamide combination to treat refractory and first bone marrow relapse adult ALL, for the achievement of a complete remission (CR) and the concurrent evaluation of biological response in ALL cells (minimal residual disease, apoptosis and DNA cell damage, pharmacogenomics).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Lymphoblastic Leukemia
CountriesItaly
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 31, 2011
Enrollment StartOct 1, 2012
Primary CompletionMar 11, 2017
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 14.7 years ago

Interventions

Clofarabine, Cyclophosphamidedrug

The proposed treatment schedule consists of a combination of Clofarabine plus Cyclophosphamide administered over 5 consecutive days (Treatment scheme).